Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CART Cells”

174 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 174 results

Early research (Phase 1)Looking for participantsNCT06934382
What this trial is testing

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Who this might be right for
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Stephan Grupp MD PhD 33
Early research (Phase 1)Looking for participantsNCT06185751
What this trial is testing

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 25
Early research (Phase 1)UnknownNCT03114670
What this trial is testing

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Who this might be right for
Adult Acute Myeloid Leukemia
Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)Looking for participantsNCT05656573
What this trial is testing

CART-PSMA Cells for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
Nova Therapeutics LLC 20
Testing effectiveness (Phase 2)UnknownNCT05286164
What this trial is testing

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

Who this might be right for
CART TreatmentB Cell Lymphoma
Tel-Aviv Sourasky Medical Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT04422912
What this trial is testing

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Who this might be right for
Pemphigus Vulgaris
Cabaletta Bio 40
Early research (Phase 1)Looking for participantsNCT07333430
What this trial is testing

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (MM)
Hadassah Medical Organization 60
Testing effectiveness (Phase 2)Study completedNCT02471430
What this trial is testing

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Who this might be right for
HIV Infection
Massachusetts General Hospital 17
Post-approval studies (Phase 4)Study completedNCT04192487
What this trial is testing

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Who this might be right for
Acquired Immunodeficiency SyndromeHealthy VolunteersHIV/AIDS+2 more
Napo Pharmaceuticals, Inc. 17
Testing effectiveness (Phase 2)Looking for participantsNCT07489534
What this trial is testing

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

Who this might be right for
Multiple Myeloma
Daihong Liu 25
Early research (Phase 1)Looking for participantsNCT07541391
What this trial is testing

Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Peter MacCallum Cancer Centre, Australia 12
Early research (Phase 1)Looking for participantsNCT06626919
What this trial is testing

Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Who this might be right for
Muscular DiseasesNeuromuscular ManifestationsAutoimmune+4 more
Arcellx, Inc. 30
Not applicableLooking for participantsNCT07180992
What this trial is testing

Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma

Who this might be right for
Multiple MyelomaMonocytesCART Cells
Centre Hospitalier Universitaire, Amiens 25
Testing effectiveness (Phase 2)WithdrawnNCT03098355
What this trial is testing

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Who this might be right for
B-Cell LeukemiaB-Cell Lymphoma
Zhujiang Hospital
Early research (Phase 1)Study completedNCT02761915
What this trial is testing

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Who this might be right for
Relapsed or Refractory Neuroblastoma
Cancer Research UK 17
Not applicableLooking for participantsNCT06333275
What this trial is testing

Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy

Who this might be right for
Vaccine Immunity in CAR-T Cell Therapy Recipients
Insel Gruppe AG, University Hospital Bern 80
Testing effectiveness (Phase 2)UnknownNCT03152435
What this trial is testing

EGFR CART Cells for Patients With Metastatic Colorectal Cancer

Who this might be right for
EGFR-positive Colorectal Cancer
Shenzhen Second People's Hospital 20
Very early researchUnknownNCT04617704
What this trial is testing

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Very early researchUnknownNCT04626726
What this trial is testing

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Adult B Acute Lymphoblastic Leukemia
Hebei Senlang Biotechnology Inc., Ltd. 50
Testing effectiveness (Phase 2)UnknownNCT04309981
What this trial is testing

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Sara V. Latorre 73
Load More Results